Skip to content

Pharma Giants Look to Shed Zantac Risks While Defending Product

  • GSK, Sanofi, Pfizer among those trying to cut exposure
  • Battle could decide which, if any, companies will owe billions

There’s a second battle emerging in the escalating legal fight over whether heartburn medicine Zantac causes cancer. 

Even as drug companies insist the product and its generic versions are safe, they’re simultaneously looking to unload as much legal risk as possible onto rivals.